UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 16, 2006
Lpath, Inc.
(Exact name of registrant specified in charter)
Nevada |
| 000-50344 |
| 16-1630142 |
(State of Incorporation) |
| (Commission File Number) |
| (IRS Employer |
|
|
|
| Identification No.) |
6335 Ferris Square, Suite A, San Diego, CA 92121
(Address of principal executive offices) (Zip Code)
(858) 678-0800
Issuer’s Telephone Number
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On August 16, 2006, Lpath, and Laureate Pharma, Inc. entered into a Development and Manufacturing Services Agreement (the “Agreement”) for the development, manufacture and storage of Lpath’s Sphingomab™ monoclonal antibody for use in clinical trials. Lpath’s total costs for the development and manufacture of its Sphingomab™ monoclonal antibody, including raw materials and fill/finish, could approximate $3.0 million over the next 15 months. The Agreement with Laureate will be filed as an exhibit to Lpath’s quarterly report on Form 10-Q for the quarter ending September 30, 2006.
Item 9.01 Financial Statements and Exhibits.
Exhibits
99.1 |
| Press Release dated August 22, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lpath, Inc. | |||
|
|
| ||
|
| By: |
| /s/Scott Pancoast |
|
| Name: Scott Pancoast | ||
|
| Title: President and Chief Executive Officer | ||
|
| Dated: August 22, 2006 | ||